Archived: 9th Winter Conference
on Medicinal & Bioorganic Chemistry
January 25th - 29th 2009
Steamboat Springs Resort, Colorado
Agenda
Sunday, January 25th 2009
Synthesis of Complex Molecules: from Natural Products to Pharmaceutical Scale Up
Program Chair: Tony Barrett, Imperial College
Mycalamides, Pederin and Related Natural Products: Chemical Synthesis and Biological Studies
Process Development and Multi Kilogram Synthesis of Inhaled UK-432,097
Practical Asymmetric Conjugate Alkynylation of Meldrum’s Acid Derived Acceptors
HDAC Inhibitors
Monday, January 26th 2009
PK/PD Modeling and Simulation: Opportunities to bridge the Drug Discovery to Drug Development Divide
Program Chair: Dennis Dean, Merck Research Laboratories
PK/PD Modeling and Simulation – Fundamentals and Applications to Drug Development
PK/PD Modeling in Candidate Selection and Early Development
Application of Imaging in Translational Drug Discovery and Development
An Animal to Human Translational PK-PD Approach Based on Brain Receptor Occupancy To Establish Clinical Dose
Novel Approaches for the Pharmacological Treatment of Pain
Program Chair: Philippe Nantermet, Merck Research Laboratories
Overview of the Field, Challenges and Opportunities
US FAAH Inhibitors for the Treatment of Pain
Molecular Mechanisms of Acquired Resistance to Kinase Inhibitors
Synthesis and Activity of 1-(3-amino-2-hydroxy-1-phenylpropyl)Indolin-2-ones and Derivatives: Discovery of Selective Norepinephrine Reuptake Inhibitor WAY-318068
CGRP Receptor Antagonists as Novel Pain Therapeutics
Tuesday, January 27th 2009
The University of Kansas Department of Medicinal Chemistry
Program Chair: Jeff Aube, University of Kansas
Identification of a Systemically Active Peptidic Kappa Opioid Receptor Antagonist and its Potential Applications
Old Drugs for New Targets: A Case Study with Novobiocin and Hsp90
Synthetic Mimics of Mammalian Cell Surface Receptors: New Tools for Drug Delivery and Probes of Cellular Biology
Utilizing Nature as a Source of New Probes for CNS Disorders
Oral Session I
Program Chair: Mike VanNieuwenhze, Indiana University
Towards the Synthesis of Selective CDK7 Inhibitors as Potential Anti-Cancer Drugs
Design of Orally Active and Highly Specific Matrix Metalloproteinase-13 Inhibitors for the Treatment of Osteoarthritis
Discovery of Potent Measles Virus RNA-Dependent RNA Polymerase Inhibitors
Discovery of Developmental Pathway Inhibitors: A Case Study for Hedgehog Pathway Modulators
The Discovery of Novel Inhibitors of 11b-Hydroxysteroid Dehydrogenase Type 1 (11b-HSD1)
Hydroxamate Based Histone Deacetylase Inhibitors with Improved Potency and Reduced Affinity for the hERG Ion Channel
Wednesday, January 28th 2009
Recent Advances in Understanding and Overcoming Drug Resistance
Program Chair: Daniel Flynn, Deciphera Pharmaceuticals
Predicting and Controlling BCR-ABL Mutation-Mediated Resistance in CML: Cornering an Escape Artist
Oncogenic Tyrosine Kinases Modulate Genomic Stability and Apoptosis to Resist Their inhibitors and Promote Malignant Disease Progression
New Mechanisms of Antibiotic Resistance, and Reversing Resistance with Small Molecules
Notre Dame Resistance to beta-Lactam Antibiotics in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Poster Session
Program Chair: Jack Hodges, Berry & Associates
Not Itemized
Thursday, January 29th 2009
Oral Session II
Program Chair: Mike Rafferty, Deciphera Pharmaceuticals
Glutamate Receptor Agonist/Antagonists
Total Synthesis and Analog Development of Oximidine II: Discovery of an Unprecedented Reductive Castro-Stephens Tandem Reaction
Modular Approach to Compound Libraries Inspired by Martinellic Acid and the Steroid Nuclear Hormones
Pyrazolopyrimidines as ATP Competitive, Highly Potent and Selective MTOR Inhibitors for Oncology
Novel Opioid Receptor Probes Derived From Structural Modification to the Neo-Clerodane Diterpene
Media Sponsors
